Infratil Shares Hit New All Time High To Lead ASX 200 Today: The Details

Infratil shares (ASX: IFT) are trading at fresh all-time highs today, leading the bluechip index on the day, after its CDC Data Centres subsidiary secured a landmark 30-year, 555MW contract with a US customer, cementing the company’s position as Australasia’s dominant hyperscale data centre operator.

IFT shares led the ASX 200 index, climbing 13.81 percent to A$11.95 and marking a new record high for the infrastructure investment company intraday at A$11.98. The rally has seen market cap swell to NZ$12.86B, with the stock outperforming the broader market by a wide margin, albeit on a bullish day for the index. Trading volumes surged as the news reverberated through institutional portfolios, with Infratil now trading well above previous resistance levels established earlier this year. The move represents one of the strongest single-day performances for a major ASX-listed infrastructure stock in recent months.

The Contract That Changed Everything

CDC Data Centres, in which Infratil holds a 49.7 percent stake, has signed what the company describes as Australia’s biggest-ever data centre contract. The agreement delivers 555 megawatts of new capacity to an investment-grade US customer over an initial 30-year term, with options to extend the arrangement by up to 20 years. The scale of the deal is extraordinary: this single contract represents roughly 40 percent of the total Australian data centre operating capacity forecast for 2025, according to company estimates.

The agreement more than doubles CDC’s total contracted capacity, pushing the figure above one gigawatt for the first time. The capacity will be delivered from campuses already under development, with operations expected to come online progressively through the 2028 and 2029 financial years. Critically, management emphasised that the contract sits entirely within CDC’s existing growth plan and will not require additional equity contributions from Infratil or other shareholders.

Guidance Reaffirmed

CDC reaffirmed its near-term earnings guidance while providing a glimpse of the longer-term earnings power unlocked by this contract. The company maintained its FY27 EBITDAF guidance range of A$680 million to A$720 million, but now expects FY28 EBITDAF to exceed A$1 billion. Once all contracted capacity is fully deployed and operational, CDC projects annualised EBITDAF of approximately A$2 billion, a figure that underscores the transformational nature of the agreement.

To support construction of the new sites, CDC expects FY27 capital expenditure of A$3.8 billion to A$4.2 billion, excluding land acquisition costs. The company’s balance sheet remains robust, with A$3.9 billion in cash and undrawn credit facilities as at 31 March. Earlier this year, CDC shareholders including Infratil provided a further A$500 million in equity to support the growth pipeline, but management stressed that the new contract does not necessitate further shareholder funding.

Moody’s recently assigned CDC’s Australian business a Baa2 investment-grade credit rating with a stable outlook, enhancing the company’s access to global debt markets and providing additional financial flexibility to fund its ambitious construction programme. The rating reflects both the quality of CDC’s contracted revenue base and the strength of its customer relationships.

The Backdrop

The contract solidifies CDC’s position as the largest data centre provider in Australasia and validates the company’s strategy of building hyperscale campuses capable of serving the most demanding AI and cloud workloads. The customer is described as a high-end, investment-grade US counterparty, suggesting one of the major technology platforms or cloud service providers that are driving unprecedented demand for data centre capacity globally.

CDC’s current development pipeline extends to 1.6 gigawatts of additional capacity through to 2034, with plans for further expansion in response to what management characterises as strong and sustained demand. The company has been steadily adding contracts over the past year, including AI-focused agreements in Melbourne and other facilities across Australia and New Zealand.

An independent valuation of CDC as at 31 March 2026 assessed the enterprise value at approximately A$20 billion and equity value at around A$15 billion, implying Infratil’s stake was worth roughly A$7.45 billion at that time. That valuation preceded the announcement of this landmark contract, suggesting scope for further upward revisions as the new capacity is built out and begins generating cash flows.

The CDC contract arrives against a backdrop of extraordinary global investment in data centre infrastructure, driven primarily by the compute-intensive requirements of artificial intelligence and machine learning workloads. Hyperscale technology companies are planning tens of billions of dollars in annual data centre capital expenditure, with industry capacity expected to roughly double by 2030 according to some forecasts.

In Australia, competitors including NEXTDC and AirTrunk are also ramping their hyperscale and AI-focused facilities, confirming the structural nature of demand growth in the region. However, the scale and duration of CDC’s new contract sets it apart, demonstrating the company’s ability to win headline deals in what has become an increasingly competitive market.

Execution Risks and Challenges Ahead

While markets celebrated the contract today, the path ahead is not without challenges. Delivering more than 500 megawatts of capacity reliably by FY28 and FY29 will require execution across construction, power infrastructure, and supply chain management. Data centre projects globally have faced delays and cost overruns due to equipment shortages, power availability constraints, and rising construction costs.

The agreement also introduces meaningful customer concentration risk. With a single US counterparty now accounting for a substantial portion of CDC’s contracted capacity, the company’s financial outcomes will depend more heavily on that customer’s long-term strategy, financial health, and capacity utilisation patterns.

Power infrastructure represents another potential bottleneck. Data centres are among the most energy-intensive facilities in the modern economy, and securing reliable, cost-effective power supply at the scale required by CDC’s expansion will be critical. Regulatory, environmental, and community scrutiny of data centre energy consumption and water usage is intensifying globally, creating potential headwinds for future approvals and expansions.

The capital intensity of CDC’s growth plan is also substantial. While the company’s current liquidity and credit rating provide a solid foundation, leverage will likely increase as construction ramps up. Rising interest rates or tighter credit conditions could pressure funding costs and valuations, even if operational execution proceeds smoothly.

What Next For IFT

For Infratil shareholders, the immediate focus will be on CDC’s ability to deliver the contracted capacity on time and within budget. The company’s track record will be tested as it scales construction activity to unprecedented levels over the next two to three years. Markets will also watch for signs of additional contract wins from CDC’s 1.6-gigawatt development pipeline, which would provide further validation of the growth thesis.

The broader question is whether AI and cloud demand will remain strong enough to absorb the massive wave of new data centre capacity being built across Australia and globally. If demand growth matches current expectations, CDC’s early-mover advantage and scale position it to capture outsized returns. If demand disappoints or pricing comes under pressure due to overcapacity, the company’s aggressive expansion could face headwinds.

For now, markets have pushed Infratil’s share price 25% higher over the past month of trading, a bullish sign that indicates confidence in what the contract means, as a step-change in CDC’s earnings power and strategic position. Record highs bring about periods of price discovery, which can be volatile in both directions as markets test out new levels of support and resistance to determine price. Keep risk in mind if you are looking at this one, with some sensible stops.